We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Sale of New DNA Sequencers Keep Pace with Growing Demand

By LabMedica International staff writers
Posted on 17 Sep 2012
A new, 3rd edition of the “DNA Sequencing Equipment and Services Markets” report by Kalorama Information (New York City, NY, USA) provides an in-depth examination of factors currently considered most influential in the DNA sequencing market, including an analysis of sales trends and an overview of currently available products. More...


Sales of DNA sequencers increased in the last year with the introduction of new systems and a growing demand for sequencing, according to the healthcare market research publisher Kalorama Information. Introductions of the Ion Torrent PGM, PacBio RS, and MiSeq grew the market nearly 5% to USD 560 million in 2011. More new technologies are expected that may further change the market and introduce price changes. "This was getting to be a stable market, but that changed in the last two years," said Justin Saeks, Kalorama analyst and author of the report; "Now it's more volatile and complicated; we think customers will acquire new systems, but pricing and feature preferences will get interesting." In addition to analyzing and forecasting DNA sequencer sales, the report also looks at sequencer consumables and services sales.

According to the report, DNA sequencing has seen very high growth in recent years as labs have decided to use next-generation sequencing, though large segments of end-users still use CE Sanger systems. The science of sequencing is constantly evolving, particularly as more clinical applications are sought and competition with other technologies is resolved. Just one of many trends: large structural variations have shown to be highly important for genetic variation (more so than SNPs) so read lengths then become a key factor in purchases. "Longer-term, questions still remain for broad areas such as disease prevention and diagnostics which could turn into home runs or strikeouts," said Mr. Saeks.

The report also examines the competitive positions of players and says competition will be intense as systems are constantly improved and new products appear. It suggests customer criteria and priorities may change so specific features might be make-or-break depending on the applications that are discovered; as specific applications place emphasis on one benefit or another, the market segments can then narrow down their usage to certain products.

Related Links:

Kalorama Information
DNA Sequencing Equipment and Services Markets, 3rd Edition



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Aspiration System
VACUSAFE
New
Multi-Chamber Washer-Disinfector
WD 390
New
Thyroid Test
Anti-Thyroid EIA Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.